Stock Analysis
Cereno Scientific Full Year 2023 Earnings: kr0.21 loss per share (vs kr0.20 loss in FY 2022)
Cereno Scientific (STO:CRNO B) Full Year 2023 Results
Key Financial Results
- Revenue: kr49.3m (down 14% from FY 2022).
- Net loss: kr48.1m (loss widened by 74% from FY 2022).
- kr0.21 loss per share (further deteriorated from kr0.20 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Cereno Scientific Earnings Insights
Looking ahead, revenue is expected to decline by 139% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Sweden are expected to grow by 18%.
Performance of the Swedish Biotechs industry.
The company's shares are down 5.2% from a week ago.
Risk Analysis
You should learn about the 4 warning signs we've spotted with Cereno Scientific (including 1 which can't be ignored).
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:CRNO B
Cereno Scientific
Cereno Scientific AB (publ), clinical stage biotechnology company, develops therapeutics to treat cardiovascular and rare diseases worldwide.